Distinct immunological signatures discriminate severe COVID-19 from non-SARS-CoV-2-driven critical pneumonia.
Adult
Angiotensin-Converting Enzyme 2
/ metabolism
Antigen Presentation
Biomarkers
/ blood
CD4-Positive T-Lymphocytes
/ immunology
COVID-19
/ immunology
Female
HLA Antigens
/ genetics
Humans
Immunity, Innate
Immunophenotyping
Male
Middle Aged
Natural Killer T-Cells
/ immunology
Pneumonia
/ immunology
SARS-CoV-2
/ immunology
Severity of Illness Index
T-Lymphocyte Subsets
/ immunology
COVID-19
GM-CSF
HLA typing
SARS-CoV-2
biomarker
high-dimensional single cell analysis
immune profiling
immunophenotyping
peptide binding strength
spectral flow cytometry
Journal
Immunity
ISSN: 1097-4180
Titre abrégé: Immunity
Pays: United States
ID NLM: 9432918
Informations de publication
Date de publication:
13 07 2021
13 07 2021
Historique:
received:
17
12
2020
revised:
24
03
2021
accepted:
04
05
2021
pubmed:
30
5
2021
medline:
23
7
2021
entrez:
29
5
2021
Statut:
ppublish
Résumé
Immune profiling of COVID-19 patients has identified numerous alterations in both innate and adaptive immunity. However, whether those changes are specific to SARS-CoV-2 or driven by a general inflammatory response shared across severely ill pneumonia patients remains unknown. Here, we compared the immune profile of severe COVID-19 with non-SARS-CoV-2 pneumonia ICU patients using longitudinal, high-dimensional single-cell spectral cytometry and algorithm-guided analysis. COVID-19 and non-SARS-CoV-2 pneumonia both showed increased emergency myelopoiesis and displayed features of adaptive immune paralysis. However, pathological immune signatures suggestive of T cell exhaustion were exclusive to COVID-19. The integration of single-cell profiling with a predicted binding capacity of SARS-CoV-2 peptides to the patients' HLA profile further linked the COVID-19 immunopathology to impaired virus recognition. Toward clinical translation, circulating NKT cell frequency was identified as a predictive biomarker for patient outcome. Our comparative immune map serves to delineate treatment strategies to interfere with the immunopathologic cascade exclusive to severe COVID-19.
Identifiants
pubmed: 34051147
pii: S1074-7613(21)00208-9
doi: 10.1016/j.immuni.2021.05.002
pmc: PMC8106882
pii:
doi:
Substances chimiques
Biomarkers
0
HLA Antigens
0
ACE2 protein, human
EC 3.4.17.23
Angiotensin-Converting Enzyme 2
EC 3.4.17.23
Banques de données
ClinicalTrials.gov
['NCT04385108']
Types de publication
Comparative Study
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1578-1593.e5Commentaires et corrections
Type : CommentIn
Type : ErratumIn
Informations de copyright
Copyright © 2021 The Author(s). Published by Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of interests The authors declare no competing interests.
Références
Mucosal Immunol. 2016 Mar;9(2):401-13
pubmed: 26220166
Cell. 2020 Oct 1;183(1):16-27.e1
pubmed: 32882182
N Engl J Med. 2020 Jul 9;383(2):120-128
pubmed: 32437596
Eur J Immunol. 2016 Jan;46(1):34-43
pubmed: 26548301
Nat Rev Immunol. 2020 Jun;20(6):355-362
pubmed: 32376901
Science. 2020 Sep 4;369(6508):1210-1220
pubmed: 32788292
Br J Cancer. 2014 Sep 23;111(7):1391-9
pubmed: 25093496
Nature. 2020 Mar;579(7798):270-273
pubmed: 32015507
Science. 2020 Mar 13;367(6483):1260-1263
pubmed: 32075877
Nat Immunol. 2019 Feb;20(2):163-172
pubmed: 30643263
Lancet. 2020 Feb 22;395(10224):565-574
pubmed: 32007145
J Virol. 2020 Jun 16;94(13):
pubmed: 32303592
N Engl J Med. 2020 Oct 15;383(16):1522-1534
pubmed: 32558485
N Engl J Med. 2020 Mar 26;382(13):1199-1207
pubmed: 31995857
Sci Immunol. 2020 Jul 10;5(49):
pubmed: 32651212
Lancet. 2020 May 2;395(10234):1417-1418
pubmed: 32325026
Nat Commun. 2020 Jul 6;11(1):3434
pubmed: 32632085
Blood. 2009 Aug 20;114(8):1537-44
pubmed: 19423728
Science. 2020 Oct 23;370(6515):
pubmed: 32972995
Proc Natl Acad Sci U S A. 2021 Feb 9;118(6):
pubmed: 33479167
Nature. 2021 Feb;590(7844):140-145
pubmed: 33137809
Nat Immunol. 2018 Feb;19(2):99
pubmed: 29348503
Clin Immunol. 2021 Jan;222:108630
pubmed: 33189887
Science. 2020 May 1;368(6490):473-474
pubmed: 32303591
Cell. 2020 Oct 1;183(1):143-157.e13
pubmed: 32877699
Nat Methods. 2019 Dec;16(12):1289-1296
pubmed: 31740819
Nat Rev Immunol. 2020 Sep;20(9):529-536
pubmed: 32728222
Nat Immunol. 2021 Mar;22(3):322-335
pubmed: 33531712
Lancet Respir Med. 2019 Aug;7(8):710-720
pubmed: 31182406
Sci Immunol. 2021 Feb 23;6(56):
pubmed: 33622974
Med Microbiol Immunol. 2020 Dec;209(6):657-668
pubmed: 32860073
Immunity. 2018 Feb 20;48(2):198-200
pubmed: 29466751
BMC Med. 2015 Feb 17;13:33
pubmed: 25855867
Clin Immunol. 2020 Oct;219:108572
pubmed: 32810602
Science. 2020 Oct 23;370(6515):
pubmed: 32972996
Science. 2020 Sep 4;369(6508):
pubmed: 32669297
Trends Immunol. 2015 Apr;36(4):265-76
pubmed: 25797516
J Exp Med. 2016 Nov 14;213(12):2621-2633
pubmed: 27821550
Nat Rev Immunol. 2020 May;20(5):269-270
pubmed: 32273594
Science. 2011 May 6;332(6030):687-96
pubmed: 21551058
Cell. 2020 Dec 10;183(6):1479-1495.e20
pubmed: 33171100
Cell Mol Immunol. 2020 May;17(5):533-535
pubmed: 32203188
Immunity. 2017 Jul 18;47(1):135-147.e5
pubmed: 28723546
Nat Med. 2019 Mar;25(3):454-461
pubmed: 30804515
Cytometry A. 2015 Jul;87(7):636-45
pubmed: 25573116
Sci Transl Med. 2020 Oct 7;12(564):
pubmed: 32958614
Anaesth Crit Care Pain Med. 2018 Feb;37(1):83-98
pubmed: 29155054
Nat Commun. 2020 Nov 17;11(1):5859
pubmed: 33203833
Cell Rep. 2014 Nov 6;9(3):1075-88
pubmed: 25437561
J Leukoc Biol. 2021 Feb;109(2):327-337
pubmed: 32421903
Anaesthesia. 2020 Oct;75(10):1340-1349
pubmed: 32602561
Psychiatry (Edgmont). 2009 Oct;6(10):21-9
pubmed: 20011465
Cell Mol Immunol. 2019 Jun;16(6):602-610
pubmed: 30327490
BMJ. 2020 Oct 14;371:m3981
pubmed: 33055076
Cell. 2019 Jun 13;177(7):1888-1902.e21
pubmed: 31178118
Nature. 2020 Aug;584(7821):463-469
pubmed: 32717743
Ann Intern Med. 2020 May 05;172(9):577-582
pubmed: 32150748
Cell. 2020 Sep 17;182(6):1419-1440.e23
pubmed: 32810438
Eur J Immunol. 2019 Feb;49(2):212-220
pubmed: 30653669
Cell. 2020 Sep 17;182(6):1401-1418.e18
pubmed: 32810439
J Exp Med. 2020 Dec 7;217(12):
pubmed: 32886755
Trials. 2020 Jun 05;21(1):491
pubmed: 32503663
J Grad Med Educ. 2012 Sep;4(3):279-82
pubmed: 23997866
Nat Rev Immunol. 2020 Aug;20(8):507-514
pubmed: 32576980
Sci Immunol. 2021 Mar 10;6(57):
pubmed: 33692097
Lancet Rheumatol. 2020 Aug;2(8):e465-e473
pubmed: 32835256
Lancet. 2020 Nov 14;396(10262):1595-1606
pubmed: 33065034
Front Immunol. 2020 Jul 03;11:1625
pubmed: 32719685
Asian Pac J Allergy Immunol. 2020 Mar;38(1):1-9
pubmed: 32105090
Nat Med. 2020 Oct;26(10):1636-1643
pubmed: 32839624
Science. 2020 Aug 7;369(6504):718-724
pubmed: 32661059
J Leukoc Biol. 2017 May;101(5):1143-1153
pubmed: 28148720
Immunity. 2014 Feb 20;40(2):289-302
pubmed: 24530057
Nat Immunol. 2020 Sep;21(9):1107-1118
pubmed: 32788748